This histogram enumerates side effects from a completed 2019 Phase 3 trial (NCT04019704) in the AXS-05 ARM group. Side effects include: All Others, occurring in <5% of Subjects with 29%, Dizziness with 16%, Nausea with 13%, Headache with 8%, Diarrhea with 7%.
2 Treatment Groups
1 of 2
1 of 2
350 Total Participants · 2 Treatment Groups
Primary Treatment: AXS-05 · Has Placebo Group · Phase 3
Experimental Group · 1 Intervention: AXS-05 · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Screening: ~3 weeks
Reporting: up to 5 weeks
Who is running the clinical trial?
Axsome Therapeutics, Inc.Lead Sponsor
23 Previous Clinical Trials
6,712 Total Patients Enrolled
3 Trials studying Alzheimer Disease
886 Patients Enrolled for Alzheimer Disease
Age 65+ · All Participants · 2 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have a clinical diagnosis of probable AD based on the 2011 NIA-AA criteria.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.